1. Home
  2. GOSS vs CAPL Comparison

GOSS vs CAPL Comparison

Compare GOSS & CAPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$2.89

Market Cap

796.2M

Sector

Health Care

ML Signal

HOLD

Logo CrossAmerica Partners

CAPL

CrossAmerica Partners

HOLD

Current Price

$20.50

Market Cap

794.8M

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOSS
CAPL
Founded
2015
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil Refining/Marketing
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
796.2M
794.8M
IPO Year
2019
2012

Fundamental Metrics

Financial Performance
Metric
GOSS
CAPL
Price
$2.89
$20.50
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$8.60
N/A
AVG Volume (30 Days)
4.4M
25.7K
Earning Date
11-05-2025
11-05-2025
Dividend Yield
N/A
10.18%
EPS Growth
N/A
129.06
EPS
N/A
1.19
Revenue
$44,051,000.00
$3,418,591,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$6.41
N/A
P/E Ratio
N/A
$17.33
Revenue Growth
N/A
N/A
52 Week Low
$0.76
$19.61
52 Week High
$3.87
$25.73

Technical Indicators

Market Signals
Indicator
GOSS
CAPL
Relative Strength Index (RSI) 39.59 46.43
Support Level $3.04 $20.20
Resistance Level $3.87 $21.17
Average True Range (ATR) 0.29 0.39
MACD -0.10 -0.03
Stochastic Oscillator 1.49 33.98

Price Performance

Historical Comparison
GOSS
CAPL

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

About CAPL CrossAmerica Partners

CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.

Share on Social Networks: